{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:25:08Z","timestamp":1792675508630,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":1847,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1093\/annonc\/mdu390","type":"journal-article","created":{"date-parts":[[2014,9,6]],"date-time":"2014-09-06T05:15:31Z","timestamp":1409980531000},"page":"2244-2251","source":"Crossref","is-referenced-by-count":157,"title":["Phase I\/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors"],"prefix":"10.1016","volume":"25","author":[{"given":"J.-C.","family":"Soria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"DeBraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bahleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dientsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Delmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Litten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D'Incalci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zucchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Camboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu390_bb0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/BJ20101603","article-title":"Fibroblast growth factors and their receptors in cancer","volume":"437","author":"Wesche","year":"2011","journal-title":"Biochem J"},{"key":"10.1093\/annonc\/mdu390_bb0015","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdu390_bb0020","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","article-title":"Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis","volume":"17","author":"Lieu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu390_bb0025","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrclinonc.2009.110","article-title":"Targeting angiogenesis: progress with anti-VEGF treatment with large molecules","volume":"6","author":"Grothey","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mdu390_bb0030","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrc909","article-title":"VEGF and the quest for tumour angiogenesis factors","volume":"2","author":"Ferrara","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdu390_bb0035","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/annonc\/mdt419","article-title":"Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors","volume":"25","author":"Dienstmann","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu390_bb0040","doi-asserted-by":"crossref","first-page":"e20351","DOI":"10.1371\/journal.pone.0020351","article-title":"Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer","volume":"6","author":"Dutt","year":"2011","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdu390_bb0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdu390_bb0050","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/1078-0432.CCR-08-1791","article-title":"Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array","volume":"15","author":"Andre","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu390_bb0055","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/bcr1665","article-title":"FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis","volume":"9","author":"Elbauomy","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdu390_bb0060","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/1078-0432.CCR-06-1164","article-title":"FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas","volume":"12","author":"Reis-Filho","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu390_bb0065","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1038\/onc.2009.489","article-title":"Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets","volume":"29","author":"Turner","year":"2010","journal-title":"Oncogene"},{"issue":"suppl 3","key":"10.1093\/annonc\/mdu390_bb0070","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1158\/0008-5472.SABCS-09-4170","article-title":"FGFR1 and FGF coamplification in breast cancer","volume":"69","author":"Albiges","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu390_bb0075","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu390_bb0080","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1158\/0008-5472.CAN-10-2700","article-title":"E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models","volume":"71","author":"Bello","year":"2011","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu390_bb0085","unstructured":"Guideline on the evaluation of anticancer medicinal products in man EMA\/CHMP\/205\/95. 13 December 2012"},{"key":"10.1093\/annonc\/mdu390_bb0090","series-title":"The Design of Clinical Trials in Cancer Therapy","first-page":"242","article-title":"Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy programme of the National Cancer Institute","author":"Carter","year":"1973"},{"key":"10.1093\/annonc\/mdu390_bb0095","series-title":"Common Terminology Criteria for Adverse Events","author":"National Cancer Institute","year":"2010"},{"key":"10.1093\/annonc\/mdu390_bb0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu390_bb0105","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/jms.1985","article-title":"Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study","volume":"46","author":"Sala","year":"2011","journal-title":"J Mass Spectrom"},{"key":"10.1093\/annonc\/mdu390_bb0110","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.ejca.2014.04.031","volume":"50","author":"Postel-Vinay","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu390_bb0115","doi-asserted-by":"crossref","first-page":"F351","DOI":"10.1152\/ajprenal.00232.2013","article-title":"Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4","volume":"306","author":"Gattineni","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1093\/annonc\/mdu390_bb0120","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"10.1093\/annonc\/mdu390_bb0125","doi-asserted-by":"crossref","first-page":"LBA6008","DOI":"10.1200\/jco.2014.32.18_suppl.lba6008","article-title":"A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT)","volume":"32","author":"Schlumberger","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu390_bb0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-010-0788-0","article-title":"Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer","volume":"121","author":"Barrios","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"10.1093\/annonc\/mdu390_bb0135","doi-asserted-by":"crossref","first-page":"LB-145","DOI":"10.1158\/1538-7445.AM2013-LB-145","article-title":"Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR) in patients with advanced solid tumors","volume":"73","author":"Andre","year":"2013","journal-title":"Cancer Res"},{"issue":"suppl 8","key":"10.1093\/annonc\/mdu390_bb0140","doi-asserted-by":"crossref","first-page":"LC-122","DOI":"10.1158\/1538-7445.AM2012-LB-122","article-title":"A phase I dose escalation study of NVP-BGJ398, a selective pan-FGRR inhibitor in genetically preselected advanced solid tumors","volume":"72","author":"Wolf","year":"2012","journal-title":"Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/11\/2244\/325838\/mdu390.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T12:14:29Z","timestamp":1689509669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419367778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0923753419367778"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu390","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}